Ponatinib

• Iclusig (ponatinib) is a kinase inhibitor indicated for the treatment of adult patients with:
• Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least a couple of prior kinase inhibitors.
• Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated.
• T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL. 

Recommended Dosage: 

CP-CML: The recommended starting dose of Iclusig is 45 mg orally with or without food once daily with a reduction to 15 mg orally once daily upon achievement of molecular response (≤1% BCR-ABL1IS). Those with loss of response can re-escalate the dose to a previously tolerated dosage of 30 mg or 45 mg orally once daily. Continue therapy until loss of response at the re-escalated dose or unacceptable toxicity. Consider discontinuing treatment in case a hematologic response has not occurred by three months.

AP-CML, BP-CML, and Ph+ ALL: The recommended starting dosage is 45 mg once daily with or without food. Continue therapy until loss of response or unacceptable toxicity. Consider reducing the dose for patients with accelerated phase (AP) CML who have achieved a major cytogenetic response. Consider discontinuing treatment in case a response has not occurred in three months.

• AOEs, including fatalities, occurred in Ponatinib-treated patients. Monitor for the existence of AOEs. Interrupt or stop treatment with Ponatinib 15 mg/45 mg tablets immediately in case of an AOE. Consider benefit-risk to guide a decision to re-initiate the treatment.
• Venous thromboembolic events (VTEs) occurred in patients treated with oral Ponatinib. Cases of pulmonary embolism have been noted, some of which were fatal. Monitor for evidence of VTEs. Interrupt or stop treatment promptly in case of a VTE.
• Heart failure (some fatal), including left ventricular dysfunction and ejection fraction decrease, occurred in Ponatinib-treated patients. Monitor for signs or symptoms persistent with heart failure and treat as clinically required. Interrupt or stop therapy in those who develop new or worsening critical heart failure.
• Hemorrhage events (some fatal), including intracranial hemorrhage, hemorrhagic gastritis, and hemorrhagic cerebral infarction occurred in Ponatinib-treated patients. Most hemorrhagic events, but not all, developed in all those with grade 3/4 thrombocytopenia. Interrupt or stop treatment in those with critical or severe hemorrhage.
• Hepatotoxicity (including fatal acute hepatic failure) has been noted. Monitor hepatic function before and during treatment. Interrupt or stop Ponatinib therapy in patients with hepatotoxicity.
• Myelosuppression (thrombocytopenia, neutropenia, and anemia) has been reported in patients treated with this therapeutic drug. Myelosuppression was managed by withholding Ponatinib 15 mg or 45 mg temporarily or reducing the dose.

What documents are required to import ICLUSIG to India?

ICLUSIG (ponatinib) tablets can be imported by patients or government hospitals on behalf of the patients. The following documentation is required:

• A valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the government of India).

How will the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the doctor.
• Import permit, if applicable.

Is ICLUSIG available in India?

ICLUSIG (ponatinib tablets) is a prescription pharmaceutical drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on a named patient supply (NPS) basis. Urgent Meds provides support for:

• Availability of ICLUSIG (ponatinib) in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, and other cities).
• Determining medicine price.
• Finding genuine and reliable sources from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

ICLUSIG can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of ICLUSIG (prescription medicine) to all locations in the world and in India after fulfilling the legal requirements, if applicable.

Please contact Urgent Meds at +1-647-818-4196 for ICLUSIG tablet pricing in India.

Email: info@urgentmeds.in

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing ICLUSIG (Medicines from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Iclusig®?

Ponatinib is the generic name for the trade name drug Iclusig®.

What is the Manufacturer’s Name of Iclusig®?

Iclusig® is manufactured by Ariad Pharmaceuticals, Inc.

Is Iclusig® approved by the FDA?

Yes, Iclusig® is approved by the FDA. Date of first approval: December 14, 2012.

Where can I get Iclusig® (ponatinib) at the best price in India?

To get the best price for Ponatinib in India, kindly contact Urgent Meds. A medical prescription is needed from a treating physician.

What is the dosage and form of Iclusig® supplied?

Iclusig® is supplied as tablets in the following strengths: 10 mg, 15 mg, 30 mg, and 45 mg for oral administration.

What are the most common side effects of Iclusig®?

The most common side effects of Iclusig® include abdominal pain, rash, arthralgia, headache, constipation, dry skin, hypertension, fatigue, fluid retention, pyrexia, nausea, pancreatitis/lipase elevation, anemia, hemorrhage, hepatic dysfunction, and AOEs.

How much does Iclusig® cost in India?

The cost of Iclusig (Ponatinib) in India can vary. To procure this kinase inhibitor legally, you can call or WhatsApp +91-9310090915 or email info@urgentmeds.in.

What are the storage conditions of Iclusig®?

Store Iclusig® tablets at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).

Is it safe to buy Iclusig® online in India?

Yes, you can buy Iclusig (Ponatinib) online in India at the best price from Urgent Meds. If this medicinal product is not yet registered or available in your country, we can help facilitate its supply through legal channels.

For more information, please contact Urgent Meds at +1-647-818-4196 or email info@urgentmeds.in. We ensure quality and delivery as per the buyer’s requirements.